Chua Wei, Moore Melissa M, Charles Kellie A, Clarke Stephen J
Concord Repatriation General Hospital, Department of Medical Oncology, Sydney Cancer Centre, Hospital Road, New South Wales 2139, Australia.
Curr Opin Mol Ther. 2009 Dec;11(6):611-22.
Targeted mAbs to VEGFR and EGFR are well-established therapies for the treatment of colorectal cancer. The costs and toxicities associated with these novel treatments are not insignificant, and therefore molecular markers that predict treatment efficacy are needed to individualize the therapy administered to each patient. Recent data in this research field support KRAS mutation testing to guide the selection of EGFR inhibitors for the treatment of colorectal cancer. This review discusses the evidence that KRAS mutation analysis can indicate a beneficial response to EGFR inhibitors, and the potential and limitations of other mutations in the VEGF and EGF signaling pathways as predictive molecular markers in this setting.
针对血管内皮生长因子受体（VEGFR）和表皮生长因子受体（EGFR）的单克隆抗体（mAbs）是治疗结直肠癌的成熟疗法。这些新型治疗方法所涉及的成本和毒性不容小觑，因此需要能够预测治疗效果的分子标志物，以便为每位患者制定个性化治疗方案。该研究领域的最新数据支持通过KRAS突变检测来指导表皮生长因子受体抑制剂治疗结直肠癌的选择。本综述讨论了KRAS突变分析可提示对表皮生长因子受体抑制剂产生有益反应的证据，以及在这种情况下，血管内皮生长因子（VEGF）和表皮生长因子（EGF）信号通路中其他突变作为预测性分子标志物的潜力和局限性。
